title: Efficacy and acceptability of the new oral phosphate binder Lenziaren(®) in healthy cats fed a renal diet.
abstract: The efficacy and acceptability of the new oral phosphate binder Lenziaren(®) (SBR759) were evaluated in healthy cats fed with a commercial diet containing low amounts of phosphate ('renal diet'). Lenziaren(®) at 0.125, 0.25, 0.5 and 1 g/day was compared to a reference product Lantharenol(®) (3.0 g/day) and a placebo in a masked, randomized, parallel-group design study in 36 cats (n = 6 per group). All products were mixed with the ration which was fed once daily for 28 days. Lenziaren(®) produced significant dose-related reductions in serum and urine phosphate concentrations, faecal apparent phosphorus digestibility and fractional urinary phosphate excretion. Cats administered Lenziaren(®) consumed significantly less food than the placebo group, but this had no negative impact on body weight or acceptability assessments. When compared to the positive control, Lantharenol(®) , Lenziaren(®) was significantly more acceptable (0.125, 0.5 and 1.0 g/day doses), was associated with higher food consumption (0.125, 0.5 and 1.0 g/day doses) and had greater efficacy in reducing serum phosphate (0.5 and 1.0 g/day) and urine phosphate concentrations (1.0 g/day). In conclusion, Lenziaren(®) was an effective oral phosphate binder in healthy cats fed with a renal diet. Lenziaren(®) was well accepted and tolerated. Dosages of 0.25-1.0 g/cat per day are recommended for clinical testing.
authors.affiliation: Novartis Animal Health Inc, Basel, Switzerland.
authors.forename: J N
authors.initials: JN
authors.lastname: King
authors.forename: P C
authors.initials: PC
authors.lastname: Delport
authors.forename: H G
authors.initials: HG
authors.lastname: Luus
authors.forename: H L
authors.initials: HL
authors.lastname: Erasmus
authors.forename: P M
authors.initials: PM
authors.lastname: Barnes
authors.forename: C
authors.initials: C
authors.lastname: Speranza
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002415:Cats / Q000378:metabolism*; D004032:Diet / Q000662:veterinary; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use*; D007811:Lanthanum / Q000627:therapeutic use; D008297:Male; D010710:Phosphates / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000097:blood / Q000652:urine; D013213:Starch / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D005290:Ferric Compounds; D010710:Phosphates; C570356:SBR 759; C119467:lanthanum carbonate; D007811:Lanthanum; D013213:Starch